US recommends ‘pause’ to Johnson & Johnson jab rollout over blood clot fears

US

The US Food and Drug Administration has recommended a “pause” to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

Officials say they are looking into six reported cases “of a rare & severe type of blood clot in individuals after receiving the vaccine”.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a statement on Twitter.

It said until the cases had been assessed for their potential significance, “we are recommending this pause”.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” it added.

Articles You May Like

Los Angeles bans oil and gas drilling within city limits
England talent and ambition finally living up to expectation – but there’s still that man Mbappe to come
Cramer talks about some hot industrial stocks, and how we’re playing Wall Street’s pivot from tech
Eighth child dies after Strep A infection – as parents warned to watch out for symptoms
Conspiracy theorist who claimed Sandy Hook victims were actors says he’s bankrupt